BRCA1 and cancer: The antagonism between 53BP1–RIF1–Shieldin and BRCA1–BARD1 has important implications for cancer therapy, in particular for targeting BRCA–deficient tumors with poly(ADP-ribose) polymerase (PARP) inhibitors, and for improving CRISPR/Cas9–mediated gene editing.